Abstract:Mycobacterium tuberculosis is a pathogen that causes tuberculosis (TB), which can invade various organs of the human body and has a high mortality. The drug resistance of tuberculosis has become an increasingly serious public health problem, which is a serious threat to the prevention and treatment of tuberculosis. The main first-line and second-line anti-tuberculosis drugs include isoniazid, rifampicin, pyrazinamide, streptomycin and quinolones, and in-depth understanding of the mechanisms of resistance to these anti-tuberculosis drugs can further guide the research and development of new drugs to fight tuberculosis.
万智敏, 向延根, 马小华, 石国民, 范仁华, 彭雪峰. 结核分枝杆菌对常见的一线和二线药物耐药机制的研究进展[J]. 实用预防医学, 2016, 23(9): 1150-1153.
WAN Zhi-min, XIANG Yan-gen, MA Xiao-hua, SHI Guo-min, FAN Ren-hua, PENG Xue-feng. Advances in the mechanism of drug resistance to common first-line and second-line drugs in Mycobacterium tuberculosis . , 2016, 23(9): 1150-1153.
[1] World Health Organization. Definitions and reporting framework fortuberculosis-2013 revision[R]. Geneva WHO,2013. [2] Vilchèze C, Morbidoni HR, Weisbrod TR, et al. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase inducesaccumulation of the FASI end products and cell lysis of Mycobacterium smegmatis[J]. J Bacteriol, 2000, 182(14): 4059-4067. [3] Slayden RA, Lee RE, Barry CE. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis[J]. Mol Microbiol, 2000, 38(3): 514-525. [4] Heym B, Zhang Y, Poulet S, et al. Characterization of the katG gene encodinga catalase-peroxidase required for the isoniazid susceptibility of Mycobacteriumtuberculosis[J]. J Bacteriol, 1993, 175(13): 4255-4259. [5] 邓叶华, 向延根, 马小华, 等. 结核分枝杆菌耐利福平和异烟肼分子机制的研究进展[J]. 实用预防医学, 2015, 22(9): 1148-1151. [6] Leung ETY, Kam KM, Chiu A, et al. Detection of katG Ser315Thr substitution in respiratory specimens from patients with isoniazid-resistant Mycobacteriumtuberculosis using PCR-RFLP[J]. J Med Microbiol, 2003, 52(11): 999-1003. [7] 金嘉琳, 张文宏, 翁心华, 等. 华东地区耐药结核分枝杆菌katG基因的变异[J].中华传染病杂志, 2007, 24(5): 301-305. [8] Morlock GP, Metchock B, Sikes D, et al. ethA, inhA, and katG loci of ethionam-ide resistant clinical Mycobacterium tuberculosis isolates[J]. Antimicrob Agents Chemother, 2003, 47(12): 3799-3805. [9] 李桂莲, 王撷秀, 赵德福. 结核分枝杆菌耐药基因的研究进展[J].中国慢性预防与控制, 2006, 14(5): 377-379. [10] 张顺宝, 张雪莲, 都方, 等. 抗结核一线药物及其主要作用靶点的突变[J].中国抗感染化疗杂志, 2005, 5(6): 381-383. [11] 熊礼宽.结核病实验诊断学[M].北京:人民卫生出版社,2003:52-62. [12] Heep M, Rieger U, Beck D, et al. Mutations in the beginning of the rpoB genecan induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis[J]. Antimicrob Agents Chemotherapy, 2000, 44(4): 1075-1077. [13] 李大为,肖春玲.结核杆菌耐药性的分子机制研究进展[J].国外医药:抗生素分册,2013,24(5):198-202. [14] Khadka JB, Rai SK, Shrestha S, et al. Study of rifampicin and isoniazid resistance mutation genes of M. tuberculosis isolates in Nepal[J]. Nepal Med Coll J, 2011, 13(3): 147-151. [15] Alifano P, Palumbo C, Pasanisi D, et al. Rifampicin-resistance, rpoB polymorphism and RNA polymerase genetic engineering[J]. J Biotechnol, 2015,202(1): 60-77. [16] Zhang Y, Scorpio A, Nikaido H, et al. Role of acid pH and deficient effluxof pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide[J]. J Bacteriol, 2009, 181(7):2044-2049. [17] Wade MM, Volokhov D, Peredelchuk M, et al. Accurate mapping of mutations ofpyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frameoligonucleotide microarray[J]. Diagn Microbiol Infect Dis, 2004, 49(2): 89-97. [18] Cheng SJ, Thibert L, Sanchez T, et al. pncA mutations as a major mechanismof pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada[J]. Antimicrob Agents Chemother, 2000, 44(3): 528-532. [19] Rodrigues VFS, Telles MA, Ribeiro MO, et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil[J]. Antimicrob Agents Chemother, 2005, 49(1): 444-446. [20] Tracevska T, Jansone I, Baumanis V, et al. Spectrum of pncA mutations in multidrug-resistant Mycobacterium tuberculosis isolates obtained in Latvia[J]. Antimicrob Agents Chemother, 2004, 48(8): 3209-3210. [21] Bifani P, Matherma B, Campo M, et al. Molecular identification of streptomycin monoresistant Mycobacterium tuberculosis related to multidrug-resistant W strain[J]. Emerg Infect Dis, 2001, 7(5):842-848. [22] 腾宏琴. 结核分枝杆菌诊断技术研究进展[J]. 中国冶金工业医学杂志, 2014, 31(5): 512-514. [23] Fernanda S, Spies, Andrezza W, et al. Streptomycin resistance and lineagespecific polymorphisms in Mycobacterium tuberculosis gidB gene[J]. Clin Microbiol, 2011, 49(7):2625-2630 [24] Perdigo J, Macedo R, Machado D, et al. GidB mutation as a phylogenetic marker for Q1 cluster Mycobacterium tuberculosis isolates and intermediate-level streptomycin resistance determinant in Lisbon, Portugal[J]. Clin Microbiol Infec, 2014, 20(5): O278-O284. [25] Ramaswamy SV, Reich R, Dou SJ, et al. Single nucleotide polymorphisms ingenes associated with isoniazid resistance in Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2003, 47(4): 1241-1250. [26] Johnson R, Jordaan AM, Pretorius L, et al. Ethambutol resistance testingby mutation detection[J]. Int J Tuberc Lung Dis, 2006, 10(1): 68-73. [27] Rustomjee R. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis[J]. Int J Tuberc Lung Dis, 2008, 12(2):128-138. [28] Tretter EM, Schoeffler AJ, Weisfield SR,et al. Crystal structure of theDNA gyrase GyrA N-terminal domain from Mycobacterium tuberculosis[J]. Proteins, 2010, 78(2):492-495. [29] Sulochana S, Narayanan S, Paramasivan CN, et al. Analysis of fluoroquinolone resistance in clinical isolates of Mycobacterium tuberculosis from India[J]. J Chemother, 2007, 19(2): 166-171. [30] Cui Z, Wang J, Lu J, et al. Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from east China in 2009[J]. BMC Infect Dis, 2011, 11(1): 78. [31] 郭婧玮, 谭云洪, 易松林, 等. 长沙市某院6535例肺结核患者耐药结果分析[J]. 实用预防医学, 2015, 22(8): 1014-1017. [32] Vilchèze C, Wang F, Arai M, et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid[J]. Nature Medicine, 2006,12(9): 1027-1029.